Clinical-stage biotech Infinity Pharmaceuticals (NASDAQ: INFI) had a big and bright Monday, with its stock closing the session more than 38% higher. The rocket that lifted it was ignited by a prominent investment bank's upgrade, the latest in a series of analyst upgrades for the stock. The newest bull for Infinity is Anupam Rama at JPMorgan Chase unit JPMorgan.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting